Hepatic Enzyme Induction with Phenobarbital and Doxorubicin Metabolism and Myelotoxicity in the Rabbit

References

• Myers C E. Anthracyclines. Cancer Chemotherapy and Biologic Response Modifiers Annual, H M Pinedo, D L Longo, B H Chabner. Elsevier Science Publishers B. V., Amsterdam 1987; Vol. 9: 36–49
   Google Scholar
• Bachur N R. Adriamycin (NSC-123127) pharmacology. Cancer Chemother Rep 1975; 6(Part 3)153–158
   Google Scholar
• Bagchi D, Bagchi M, Hassoun E A, et al. Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology 1995; 95: 1–9
   PubMed Web of Science ®Google Scholar
• Foglesong P, Reckord D. C, Swink S. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol 1992; 30: 123–125
   PubMed Web of Science ®Google Scholar
• Tewey K M, Rowe T C, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466–468
   PubMed Web of Science ®Google Scholar
• Schott B, Robert J. Comparative activity of anthracycline 13-di-hydromeuibolites against rat glioblastoma cells in culture. Biochem Pharmacol 1980; 28: 4069–4074
   Google Scholar
• Sinha B, Sik R H. Binding of [l4C]-adriamycin to cellular macromolecules in vivo. Biochem Pharmacol 1980; 29: 1867–1868
   PubMed Web of Science ®Google Scholar
• Dodion P, Akman S R, Tamburini J M, et al. Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system. J Pharmacol Exp Ther 1986; 237: 271–274
   PubMed Web of Science ®Google Scholar
• Cummings J, Allan L, Willmott N, et al. The enzymology of doxorubicin quinone reduction in tumor tissue. Biochem Pharmacol 1992; 44: 2175–2183
   PubMed Web of Science ®Google Scholar
• Gerwitz D, Yanovich A. S. Metabolism of adriamycin in hepatocytes isolated from the rat and rabbit. Biochem Pharmacol 1987; 36: 1793–1798
   PubMed Web of Science ®Google Scholar
• Benjamin R S, Riggs C E, Jr, Bachur N R. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 1977; 37: 1416–1420
   PubMed Web of Science ®Google Scholar
• Chabner B A, Myers C E, Oliverio V T. Clinical pharmacology of anticancer drugs. Semin Oncol 1977; 4: 165–191
   PubMed Web of Science ®Google Scholar
• Minow R A, Benjamin R S, Gottlieb J A. Adriamycin (NSC-123127) cardiomyopathy—an overview with determination of risk factors. Cancer Chemother Rep 1975; 6(Part 3)195–201
   Google Scholar
• Brenner D E, Collins J C, Hande K R. The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. Cancer Chemother Pharmacol 1986; 18: 219–222
   PubMed Web of Science ®Google Scholar
• Harris N, Brenner L. DE, Anthony L B. The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. Cancer Chemother Pharmacol 1988; 21: 323–328
   PubMed Web of Science ®Google Scholar
• Rushing D A, Raber S R, Rodvold K A, et al. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994; 74: 834–841
   PubMed Web of Science ®Google Scholar
• Bock K W, Bock-Hennig B S. Differential induction of human liver UDP-glucuronyltransferase activities by phenobarbital-type inducers. Biochem Pharmacol 1987; 36: 4137–4143
   PubMed Web of Science ®Google Scholar
• Conney A H. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967; 19: 317–366
   PubMed Web of Science ®Google Scholar
• Cusack B J, Tesnohlidek D A, Loseke V L, et al. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 1988; 22: 294–298
   PubMed Web of Science ®Google Scholar
• Reich S D, Bachur N R. Alterations in adriamycin efficacy by phenobarbital. Cancer Res 1976; 36: 3803–3806
   PubMed Web of Science ®Google Scholar
• Takanashi S, Bachur N R. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Disp 1976; 4: 79–87
   PubMed Web of Science ®Google Scholar
• Brenner D E, Galloway Noone S. R, et al. Improved high performance liquid chromatography assay of doxorubicin. Comparison to thin layer chromatography. Cancer Chemother Pharmacol 1985; 13: 139–145
   Google Scholar
• Brenner D E, Harris N L, Anthony L B, et al. The effect of allyl alcohol induced sublethal damage upon doxorubicin metabolism and toxicity in rabbits. Cancer Res 1987; 47: 3259–3265
   PubMed Web of Science ®Google Scholar
• Kivisto K T, Kroemer H K, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523–530
   PubMed Web of Science ®Google Scholar
• Cummings J, Milstead Cunningham R. D, et al. Marked interpatient variation in adriamycin biotransformation to 7-deoxyagly-cones: evidence from metabolites identified in serum. Eur J Cancer Clin Oncol 1986; 22: 991–1001
   PubMedGoogle Scholar
• Bolanowska W, Gessner T. Body residue and metabolism of adriamycin and daunorubicin in control and phenobarbital-pretreated mice. Xenobiotica 1982; 12: 125–136
   PubMed Web of Science ®Google Scholar
• Cummings J, Merry S, Willmott N. Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS). Eur J Cancer Clin Oncol 1986; 22: 451–460
   PubMedGoogle Scholar
• Riggs C E, Jr., Benjamin R, Serpick S. AA, et al. Biliary disposition of adriamycin. Clin Pharmacol Ther 1977; 22: 234–241
   PubMed Web of Science ®Google Scholar
• Goeptar A, Te R., Koppele J, Lamme M. EK, et al. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 1993; 44: 1267–1277
   PubMed Web of Science ®Google Scholar
• Henderson E S. The granulocytopenic effects of cancer chemotherapeutic agents. Drugs and Hematologic Reactions, N V Dimitrov, J H Nodine. Grune & Stratton, New York 1974; 207–221
   Google Scholar